Clinical Trials Search
Clinical Trial 18141
Interventions:748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Study Type: Treatment
Phase of Study: Phase II
- Jonathan Strosberg
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
The purpose of this study is to test any good and bad effects of the study drug called Ibrutinib.
The primary purpose of the study is to determine the objective response rate to ibrutinib therapy in patients with advanced (unresectable or metastatic) low to intermediate grade carcinoid tumors or pNETs. Secondary Objectives are: To investigate the progression-free survival (PFS) and overall survival (OS) associated with ibrutinib in patients with advanced carcinoid tumors or pNETs; To evaluate the duration of response of carcinoid or pNET patients receiving ibrutinib; To assess changes in tumor markers and changes in quality of life (QOL) in NET patients administered with ibrutinib; To determine the safety and tolerability of ibrutinib in this patient population.